Sugi Predict

Sugi Predict / Compounds / SCHEMBL564602

SCHEMBL564602

SCHEMBL564602

Nc1ccc(S(=O)(=O)c2ccccc2)cc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ HTR6 P50406 6/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ PKM P14618 2/20 0.52
▸ POLB P06746 2/20 0.47
▸ GFER P55789 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ LMNA P02545 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CA12 O43570 2/20 0.44
▸ CA1 P00915 2/20 0.44
▸ CA2 P00918 2/20 0.44
▸ CA9 Q16790 2/20 0.44
▸ HKDC1 Q2TB90 1/20 0.44
▸ CA3 P07451 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30473321 0.90 GAA (0.69) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL1732418 0.90 GAA (0.69) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL273153 0.90 GAA (0.69) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL29400283 0.90 GAA (0.69) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL564590 0.87 HTR6 (0.69) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL564630 0.87 GAA (0.60) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL564760 0.86 LMNA (0.69) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL564658 0.86 GAA (0.59) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL565124 0.85 GAA (0.81) GAAMAPTHTR6ALDH1A1PKM
SCHEMBL9328690 0.84 CA12 (0.55) GAAMAPTHTR6ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10973831-B2 Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists SUVEN LIFE SCIENCES LIMITED (IN) 2021-04-13 — — US disclosed
CN-111051302-B Fluoropiperidine compounds as pure 5-HT 6receptor antagonists 苏文生命科学有限公司 2021-04-09 — — CN disclosed
EP-3649124-B1 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS SUVEN LIFE SCIENCES LTD (IN) 2021-03-03 — — EP disclosed
EP-3649124-B1 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS SUVEN LIFE SCIENCES LTD (IN) 2021-03-03 — — EP disclosed
US-20200155560-A1 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS SUVEN LIFE SCIENCES LIMITED (IN) 2020-05-21 — — US disclosed
EP-3649124-A1 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS Suven Life Sciences Limited (IN) 2020-05-13 — — EP disclosed
CN-111051302-A As pure 5-HT6Fluoropiperidine compounds as receptor antagonists 苏文生命科学有限公司 2020-04-21 — — CN disclosed
WO-2019030641-A1 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS SUVEN LIFE SCIENCES LIMITED (IN) 2019-02-14 — — WO disclosed
WO-2019030641-A1 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS SUVEN LIFE SCIENCES LIMITED (IN) 2019-02-14 — — WO disclosed
US-8674029-B2 Method of preparing stabilized polymeric systems using polymeric peroxides Sunocs LLC (US) 2014-03-18 — — US disclosed
US-7378415-B2 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2008-05-27 — — US disclosed
US-7378415-B2 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2008-05-27 — — US disclosed
US-7378415-B2 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2008-05-27 — — US disclosed
CN-101031554-A Benzoxazine and quinoxaline derivatives and uses HOFFMANN LA ROCHE (CH) 2007-09-05 — — CN disclosed
EP-1797051-A1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES F. Hoffmann-Roche AG (CH) 2007-06-20 — — EP disclosed
US-20060208227-A1 Antioxidant and bisaminophenol derivative IDEMITSU LOSAN CO., LTD (JP) 2006-09-21 — — US disclosed
US-20060106012-A1 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC 2006-05-18 — — US disclosed
WO-2006037481-A1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES F.HOFFMANN-LA ROCHE AG (CH) 2006-04-13 — — WO disclosed
EP-1612254-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2006-01-04 — — EP disclosed
US-4219473-A Substituted unsymmetrical azo, azomethine 1:2 chromium complexes CIBA-GEIGY CORPORATION (US) 1980-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155560-A1 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS HTR6, HTR5A, HTR1B GAA 3728/4885MAPT 2944/4885HTR6 1/4885
US-10973831-B2 Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists HTR6, HTR5A, HTR1B GAA 3728/4885MAPT 2944/4885HTR6 1/4885
US-20060106012-A1 Benzoxazine and quinoxaline derivatives and uses thereof XDH, PDHX, HAX1 GAA 1409/4885MAPT 4098/4885HTR6 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.